Results 101 to 110 of about 10,523 (190)

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis

BMC Musculoskeletal Disorders
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear.
Ding-Qiang Chen, Wen-Bin Xu, Ke-Yi Xiao, Zhi-Qiang Que, Jin-Yi Feng, Nai-Kun Sun, Di-Xin Cai, Gang Rui   +7 more
doaj   +1 more source

PCSK9 inhibitors in the current management of atherosclerosis

Archivos de Cardiología de México, 2017
The history of proprotein convertase subtilisin/kexin type 9 (PCSK9) in medical science is fascinating and the evolution of knowledge of its function has resulted in new medications of major importance for the cardiovascular (CV) patient. PCSK9 functions as a negative control or feedback for the cell surface receptors for low-density lipoprotein ...
openaire   +2 more sources

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism

Scientific Reports
Doxorubicin (DOX) is an anthracycline class of chemotherapy drug, the application of which is limited due to its cardiotoxic effects. Recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), is a serine protease pivotal in lipid metabolism and ...
Shuai Shi, Zhihui Qin, Chang Liu, Yanru Zhao, Xiaopeng Bai, Chaoyu Sun, Xu Li, Wanting Cong, Xinyue Yuan, Lixiu Sun, Bingchen Liu, Xueqi Li   +11 more
doaj   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries

Frontiers in Pharmacology
The application of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represents a crucial milestone in the field of lipid-lowering therapy.
Hui-Hui Liu, Sha Li, Jian-Jun Li
doaj   +1 more source

Association Between PCSK9 Inhibitor Use and Risk of Age-Related Macular Degeneration. [PDF]

Transl Vis Sci Technol
Tsai CY, Weng CH, Tsai CY, Sheen YJ, Chen JP, Chen HM, Wang IJ, Chou CC.   +7 more
europepmc   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]

Lipids Health Dis
Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B.   +12 more
europepmc   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Role of PCSK9 inhibitors in the management of dyslipidaemia

Indian Heart Journal
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to ...
openaire   +3 more sources

Potential bias in observational PCSK9 inhibitor study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Blais JE, Wong AYS.
europepmc   +1 more source